BPC-157 and ipamorelin are frequently compared (and stacked) in fitness circles, but they do different jobs. BPC-157 is studied for local tissue repair — tendons, gut, soft tissue — based on animal data. Ipamorelin is a growth-hormone secretagogue that prompts the body's own GH for recovery and body composition. Neither is approved, and both are banned in sport.
At a glance
| BPC-157 | Ipamorelin | |
|---|---|---|
| Class | Gastric pentadecapeptide | GHRP (ghrelin-receptor agonist) |
| Studied for | Tendon, gut & soft-tissue healing | Growth-hormone release, recovery |
| Mechanism | Local repair / angiogenesis (animal data) | Triggers a GH pulse |
| Evidence | Animal studies; no completed human trials | Limited human outcome data |
| FDA status | Not approved (research chemical) | Not approved (research chemical) |
| Sport status | Banned (WADA) | Banned (WADA) |
The bottom line
Bottom line: These aren't really rivals — they target different systems (local tissue repair vs systemic growth hormone), which is exactly why they're often discussed as a "stack." But both are unapproved research chemicals with limited or animal-only human evidence, and both are prohibited in sport. Popularity outpaces the proof for each.
Frequently asked questions
What's the difference between BPC-157 and ipamorelin?
BPC-157 is studied for local tissue and gut healing (mostly animal data), while ipamorelin is a growth-hormone secretagogue that triggers the body's own GH for recovery. They work through different systems.
Can you stack BPC-157 and ipamorelin?
They're often combined in fitness use because they target different mechanisms — local repair vs systemic growth hormone — but neither has strong human evidence, both are unapproved research chemicals, and both are banned in sport.
Are either approved?
No. Both BPC-157 and ipamorelin are sold as research chemicals, are not FDA-approved, and are prohibited at all times under the World Anti-Doping Agency code.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. Peer-reviewed study
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. Peer-reviewed study
- Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-eNOS pathway. Sci Rep. 2020. Peer-reviewed study
- Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025. Peer-reviewed study
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. Peer-reviewed study
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. Peer-reviewed study
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. Peer-reviewed study
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: growth hormone secretagogues in the management of body composition in hypogonadal males. Transl Androl Urol. 2020. Peer-reviewed study
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999. Peer-reviewed study
- Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024. Peer-reviewed study
- Gouda M, Ganesh CB. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Anim Reprod Sci. 2024. Peer-reviewed study
- Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. Peer-reviewed study